ArticleObesity surgery2026
Does Metabolic and Bariatric Surgery Reduce the Risk of Developing Parkinson's Disease: A Propensity Score Matching Analysis Using Data from the National Inpatient Sample.
Article in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAlthough metabolically unhealthy obesity is an established independent risk factor for Parkinson’s disease, large-scale epidemiological evidence is lacking on whether metabolic and bariatric surgery (MBS), an obesity treatment, reduces Parkinson’s disease risk in people with obesity. This study aimed to evaluate the impact of MBS on Parkinson’s disease prevalence in people with obesity.
methodsThis multicenter, cross-sectional study utilized data from the 2018–2019 National Inpatient Sample (NIS) database. Hospitalized adult patients with obesity were stratified into MBS and non-MBS groups based on surgical history. Propensity score matching (PSM) balanced demographics and associated medical problems. Pearson’s chi-square test, Wilcoxon rank-sum test, and logistic regression assessed the association between MBS and Parkinson’s disease risk.
resultsFrom 2018 to 2019, 1,635,715 patients with obesity met inclusion criteria: 49,969 with MBS history (MBS group) and 1,585,746 without (non-MBS group). After PSM, the MBS group had significantly lower overall Parkinson’s disease prevalence (0.4% vs. 0.6%, p < 0.001) and primary Parkinson’s disease prevalence (0.4% vs. 0.6%, p < 0.001) than the non-MBS group. Undergoing MBS was independently associated with significantly reduced overall and primary Parkinson’s disease risk.
conclusionThis study suggests that people with obesity who undergo MBS were associated with a significant 30% reduction in primary and overall Parkinson’s disease risk. MBS did not significantly affect secondary Parkinson’s disease risk. This suggests MBS may specifically modulate Parkinson’s disease pathology; future research should investigate different procedures and timing for precise prevention in high-risk populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.